Nanologica to attend BIO-Europe Spring 2019 in Vienna for partnering discussions
Nanologica will be attending BIO-Europe Spring 2019 in Vienna, Mar. 25 – 27 to meet with potential pharmaceutical partners regarding co-development and licensing of NIC-001, Nanologica’s drug candidate for treating gastroparesis, as well as seeking partnership for further drug delivery applications using NLAB Silica™.Nanologica strives to be the world leader in nanoporous silica particles in its two business areas: Drug Delivery and Chromatography. Nanologica has developed a drug delivery platform based on its nanoporous silica particles, NLAB Silica™, for improved delivery and absorption